文献速递脑血管病

DAWN试验亚组分析:不同发病模式对血管内取栓获益的影响

Benefit of Endovascular Thrombectomy by Mode of Onset: Secondary Analysis of the DAWN Trial.
PubMed 文献 · Stroke · 2019-10-01

本研究为DAWN试验预设的二次分析,纳入206例发病6至24小时且存在临床-梗死不匹配的急性卒中患者,比较醒后卒中、目击发病及未目击发病三种模式下取栓与标准药物治疗的疗效。结果显示,取栓在90天改良Rankin量表0-2分比例上的获益在各发病模式间无显著差异,发病模式并非功能独立的预测因素。

要点

  • 醒后卒中占55.3%,目击发病12.1%,未目击发病32.5%。
  • 取栓组90天mRS 0-2分率在各发病模式间无统计学差异(P=0.79)。
  • 取栓对比药物治疗的获益在各发病模式中均维持(交互P=0.79)。

核心结论

  • 对于发病6至24小时且存在临床-梗死不匹配的急性缺血性卒中患者,取栓获益在醒后、未目击及目击发病三种模式间相似。

研究设计与样本

  • DAWN试验预设的二次分析,为多中心、前瞻性、随机、终点盲法评估的临床试验。
  • 纳入206例发病6至24小时且存在临床-梗死不匹配的急性卒中患者,比较Trevo取栓装置与标准药物治疗。

主要发现

  • 发病模式分布:醒后卒中55.3%(n=114),目击发病12.1%(n=25),未目击发病32.5%(n=67)。
  • 从最后正常时间至随机化的中位时间分别为:醒后卒中13.4±3.7小时,目击发病10.0±3.7小时,未目击发病14.1±4.9小时。
  • 取栓组90天mRS 0-2分率及症状性颅内出血率在各发病亚型间无统计学差异(P=0.79和P=0.40)。
  • 取栓对比对照组的90天mRS 0-2分率:醒后卒中49.3% vs 10.6%,目击发病63.6% vs 21.4%,未目击发病41.4% vs 13.2%(交互P=0.79)。
  • 在单变量和多变量分析中,发病模式未被确定为90天mRS 0-2分的显著预测因素。

临床怎么用

  • 对于发病6至24小时且存在临床-梗死不匹配的急性卒中患者,无论醒后、目击或未目击发病,均可考虑血管内取栓治疗。

局限性

  • 本研究为DAWN试验的二次分析,样本量有限(n=206),部分亚组(如目击发病n=25)样本量较小。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Background and Purpose- It is unknown whether the benefit of thrombectomy in late presenting acute stroke patients with imaging evidence of clinical-infarct mismatch is different in patients presenting with wake-up stroke compared with those presenting with witnessed onset or unwitnessed onset. Methods- Prespecified secondary analysis was performed from DAWN (Diffusion Weighted Imaging [DWI] or Computerized Tomography Perfusion [CTP] Assessment With Clinical Mismatch in the Triage of Wake Up and Late Presenting Strokes Undergoing Neurointervention), a multicenter, prospective, randomized clinical trial with blinded end point assessment comparing thrombectomy with the Trevo device against standard medical therapy in patients with acute stroke and clinical-infarct mismatch presenting 6 to 24 hour after the time last seen well. For the purposes of this study, the primary outcome was the proportion of modified Rankin Scale score 0 to 2 at 90 days. Univariable analysis and multivariable logistic regression was used to assess the relationship between outcome and mode of onset. Results- All 206 enrolled patients were included in the study. Mode of onset was: wake-up stroke (55.3%, n=114), witnessed onset (12.1%, n=25), and unwitnessed onset (32.5%, n=67) with median time last seen well to randomization (13.4±3.7, 10.0±3.7, 14.1±4.9 hours) respectively. Rates of 90-day modified Rankin Scale score of 0 to 2 and symptomatic intracerebral hemorrhage in the thrombectomy arm were not statistically different across patient onset subtypes (P=0.79 and P=0.40, respectively). The benefit of thrombectomy compared with best medical therapy was maintained across all 3 onset modes (rates of 90-day modified Rankin Scale score of 0 to 2 in patients allocated to thrombectomy versus control: wake-up stroke-49.3% versus 10.6%, witnessed onset-63.6% versus 21.4%, UW-41.4% versus 13.2%; P×interaction=0.79). In univariable and multivariable analyses, mode of onset was not identified as a significant predictor of modified Rankin Scale score 0 to 2 at 90 days. Conclusions- In patients with acute ischemic stroke presenting between 6 and 24 hours from time last seen well and harboring clinical-infarct mismatch, the benefit of thrombectomy was similar regardless of the wake-up, unwitnessed, or witnessed mode of onset.

来源:Stroke,查看原文。版权归原作者所有。

引用

  1. Jadhav AP, Aghaebrahim A, Jankowitz BT, et al. Benefit of Endovascular Thrombectomy by Mode of Onset: Secondary Analysis of the DAWN Trial. Stroke. 2019. PMID: 31570085. doi:10.1161/STROKEAHA.119.025795

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。